Intervention

Benralizumab

ClinicalTrials.gov intervention label

Clinical trials39

Recruiting2

Common conditions16

Lead sponsors shown15

Clinical trials

39 shown

Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued TreatmentNCT07444567 · 2026-07-24

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and EndotypingNCT06385236 · 2024-02-19

Fasenra: An Asthma StudyNCT07654842 · 2026-07-01

ENROLLING_BY_INVITATION

STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaNCT06465485 · 2024-02-28

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast CancerNCT05966584 · 2023-07-06

Beyond the Eosinophil: Understanding the Impact of Eosinophil Depletion on T2 Inflammation. (BEUTI)NCT05847452 · 2023-05-22

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic AsthmaNCT05692180 · 2023-04-05

ACTIVE_NOT_RECRUITING

Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)NCT05273359 · 2023-04-01

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory ImagingNCT05552508 · 2022-10-11

Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRINCT03733535 · 2022-03-01

ACTIVE_NOT_RECRUITING

FAsenra Safety Trial in IndiaNCT05384938 · 2021-11-19

Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma CentresNCT05932849 · 2021-10-05

Similarities and Differences of Biological Therapies for Severe Asthma.NCT04665141 · 2021-04-07

Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)NCT04098718 · 2021-03-29

A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypeNCT04718389 · 2021-01-26

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic AsthmaNCT04305405 · 2019-11-21

Benralizumab Airway Remodeling Study in Severe Eosinophilic AsthmaticsNCT03953300 · 2019-10-08

ACTIVE_NOT_RECRUITING

Benralizumab Exacerbation StudyNCT04102800 · 2019-09-30

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsNCT04053634 · 2019-08-26

Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic AsthmaNCT03652376 · 2018-09-01

Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe AsthmaNCT03557307 · 2018-08-01

Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody TherapiesNCT03470311 · 2018-04-26

The Effect of Benralizumab on Exercise-induced BronchoconstrictionNCT03327701 · 2017-12-01

Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)NCT03186209 · 2017-09-07

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyNCT03010436 · 2017-04-15

ACTIVE_NOT_RECRUITING

Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy VolunteersNCT02968914 · 2017-01-04

Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at HomeNCT02918071 · 2016-11-10

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic InflammationNCT02869438 · 2016-11-09

Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic AsthmaticsNCT02821416 · 2016-10-11

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe AsthmaNCT02814643 · 2016-07-01

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 AgonistNCT02808819 · 2016-06-30

Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at HomeNCT02417961 · 2015-04-27

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent AsthmaNCT02322775 · 2015-02-02

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABANCT02258542 · 2014-11-19

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS TherapyNCT02075255 · 2014-04-28

Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled AsthmaNCT01947946 · 2013-11-01

Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled AsthmaNCT01928771 · 2013-09-19

Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 AgonistNCT01914757 · 2013-08-01

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).NCT00768079 · 2009-02-02

Common conditions

Asthma28 Severe Eosinophilic Asthma3 Chronic Obstructive Pulmonary Disease2 Asthma, Exercise-Induced1 Asthma; Eosinophilic1 Breast Cancer1 Chronic Obstructive Pulmonary Disease (COPD)1 COPD1 Eosinophilic Asthma1 Eosinophilic Granulomatosis With Polyangiitis (EGPA)1 Hypereosinophilic Syndrome (HES)1 In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India1 Moderate to Severe Asthma1 Severe Asthma1 Severe Prednisone Dependent Eosinophilic Asthma1 Severe Uncontrolled Asthma1

Leading sponsors

AstraZeneca24 Clinica Universidad de Navarra, Universidad de Navarra1 Dr. Grace Parraga1 Endeavor Health1 GlaxoSmithKline1 Guy's and St Thomas' NHS Foundation Trust1 Louis-Philippe Boulet1 McMaster University1 MedImmune LLC1 Memorial Sloan Kettering Cancer Center1 National Jewish Health1 NHS Greater Glasgow and Clyde1 Temple University1 University of California, San Diego1 University of Oxford1

Trial status mix

COMPLETED24

UNKNOWN6

ACTIVE_NOT_RECRUITING4

RECRUITING2

TERMINATED2

ENROLLING_BY_INVITATION1

Phase mix

PHASE322

PHASE47

PHASE25

NA1

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.